NasdaqGS:CYTKBiotechs
Cytokinetics (CYTK) Stock Sees MYQORZO Momentum Collide With Mounting Losses
Cytokinetics walked into this earnings print with a strong growth reputation and a stock that had already cooled, down over the past month, and the market just pushed it lower again. Shares fell about 6% today, even as the headline story was clear early traction for its new cardiomyopathy drug MYQORZO and rising product revenue.
The gap is simple. The commercial ramp is starting to show up in the top line, yet the income statement still reflects heavy investment. Cytokinetics posted Q2...